The effect of Low-Intensity Cycling Exercise Combined with Blood Flow Restriction on VO2max, Muscle Strength, and Muscle Thickness
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background The aim of this study is to investigate the effects of low-intensity cycling exercise combined with blood flow restriction (BFR) on VO 2 max, muscle strength, and muscle thickness. Methods Twenty-four sedentary male participants volunteered for the study and were divided into three groups, each consisting of eight individuals: cycling exercise group (CEG; 40% VO 2 max, 40 minutes), cycling exercise with blood flow restriction group (CBFRG; 40% VO 2 max, limb occlusion pressure (LOP) at 60–80%, 15 min), and control group (CG; 40% VO 2 max, 15 minutes). The isokinetic knee strength parameters, muscle thickness, and VO 2 max values of participants were measured twice, at the beginning of the study and at the end of the ninth week. Data were analysed using two-way repeated measures ANOVA. Results The analysis revealed significant improvements in muscle thickness and VO 2 max parameters favouring post-tests for both the CEG and the CBFRG. In inter-group comparisons, significant advantages for the CBFRG were identified in the respiratory exchange ratio (RER) and vastus lateralis (VL) muscle thickness in both legs. Other parameters showed similar improvements across the groups. Additionally, peak torque (PT) at an angular velocity 180° s−1 in the left leg quadriceps (Q, F = 5.53; p = 0.021; η²=0.34) and mean power (MP) in the right leg quadriceps demonstrated significant benefits for the CBFRG. Conclusions The study concludes that low-intensity cycling combined with BFR significantly enhances VO 2 max, muscle strength, and muscle thickness, with improvements comparable to those obtained from high-intensity cycling exercises. Therefore, low-intensity cycling exercise with BFR can be considered a robust alternative to traditional high-intensity cycling exercises. Trial registration: Current Controlled Trials NCT07114835 08/08/2025